Clinical Report: Expanding the Therapeutic Landscape in Wet Age-related Macular Degeneration

Overview

This report highlights emerging therapeutic innovations in wet age-related macular degeneration (AMD), particularly focusing on sustained-release delivery platforms and multi-target inhibitors. The introduction of small-molecule tyrosine kinase inhibitors (TKIs) and bispecific antibodies like faricimab represents a significant advancement in managing this condition.

Background

Wet AMD is a leading cause of vision impairment in older adults, necessitating effective management strategies to prevent irreversible vision loss. Current treatments, primarily anti-VEGF therapies, have limitations, including treatment burden and incomplete responses in some patients. Understanding the multifactorial nature of wet AMD has opened avenues for novel therapies that target various pathways involved in the disease.

Data Highlights

No numerical data available in the source material.

Key Findings

• Anti-VEGF therapy has been the cornerstone of wet AMD management for two decades.
• Newer agents like faricimab target both VEGF-A and angiopoietin-2, enhancing vascular stability.
• Small-molecule TKIs, such as axitinib and vorolanib, are in advanced clinical development for wet AMD.
• Sustained-release formulations may reduce treatment burden and improve long-term outcomes.
• OTX-TKI demonstrated a favorable safety profile in a Phase 1 study and is being evaluated in pivotal Phase 3 trials.

Clinical Implications

The development of TKIs and sustained-release formulations may significantly reduce the frequency of injections required for wet AMD treatment, thereby improving patient adherence and outcomes. Clinicians should stay informed about these emerging therapies as they may offer more durable solutions for managing wet AMD.

Conclusion

The evolving landscape of wet AMD treatment, characterized by innovative therapies and delivery systems, holds promise for enhancing patient care and outcomes. Continued research and clinical trials will be essential to validate these advancements.

References

1. Retinal Physician, April 2024 -- Gene Therapy for Wet Age-related Macular Degeneration
2. Retinal Physician, May 2025 -- Clinical Trial Update
3. Retinal Physician, May 2024 -- Clinical Trial Update
4. Systematic review of clinical practice guidelines for the management of neovascular age-related macular degeneration | Eye
5. Overview | Faricimab for treating wet age-related macular degeneration | Guidance | NICE
6. Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results - ScienceDirect
7. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2 - PubMed
8. retinal physician — Innovative Therapies in the nAMD Pipeline: What’s Coming Next?
9. Systematic review of clinical practice guidelines for the management of neovascular age-related macular degeneration | Eye
10. Overview | Faricimab for treating wet age-related macular degeneration | Guidance | NICE
11. Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results - ScienceDirect
12. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2 - PubMed
13. Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial - ScienceDirect
14. Aflibercept 8 mg treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: guidance from a UK expert panel | Eye
15. AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
16. Efficacy of faricimab secondary to anti-vascular endothelial growth factor agents in patients with neovascular age-related macular degeneration: a systematic review and meta-analysis | Eye